{
  "id": "biomarker-compliance-main",
  "display_name": "Biomarker Testing Compliance",
  "cohort": "All Solid Tumors, Biomarker Testing Compliance (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "Significant variation in biomarker testing compliance across cancer types. NSCLC achieves 87% compliance while colorectal lags at 62%, representing $375,000 in untapped precision therapy opportunities.",
  "chart": {
    "type": "bar",
    "unit": "cancer",
    "data": [
      { "name": "NSCLC", "value": 87, "gap": 12, "highlight": false },
      { "name": "Breast", "value": 83, "gap": 8, "highlight": false },
      { "name": "Melanoma", "value": 80, "gap": 5, "highlight": false },
      { "name": "Gastric", "value": 71, "gap": -4, "highlight": false },
      { "name": "Prostate", "value": 65, "gap": -10, "highlight": true },
      { "name": "Colorectal", "value": 62, "gap": -13, "highlight": true }
    ],
    "benchmark": 75,
    "nccn_target": 90
  },
  "financial_impact": {
    "annual_opportunity": "$375,000/year",
    "math": "$375,000/year = 11.5% testing gap × 85 targeted therapy candidates × $38,000 margin per patient"
  },
  "clinical_impact": {
    "description": "Optimizing biomarker testing can significantly improve patient outcomes through precision therapy matching.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+5.4 months",
        "description": "Improved progression-free survival with matched therapies"
      },
      {
        "type": "OS",
        "value": "+8.3 months",
        "description": "Overall survival benefit with biomarker-matched treatment"
      },
      {
        "type": "ORR",
        "value": "+32%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "TTF",
        "value": "-63%",
        "description": "Reduced treatment failure rates with precision medicine"
      },
      {
        "type": "QoL",
        "value": "+24%",
        "description": "Improved quality of life with targeted approaches"
      }
    ],
    "quantitative": "+8.3 months OS"
  },
  "peer_comparison": {
    "description": "Top-performing oncology practices achieve >85% biomarker testing compliance across all tumor types vs. your 75% average, resulting in improved clinical outcomes and financial performance.",
    "peer_benchmark": 85,
    "financial_impact": {
      "annual_opportunity": "$520,000/year",
      "math": "$520,000/year = $375,000 direct therapy opportunity + $145,000 clinical trial enrollment"
    },
    "action_steps": [
      {
        "text": "Implement reflex biomarker testing protocols in pathology",
        "icon": "document"
      },
      {
        "text": "Develop cancer-specific biomarker order sets in EHR",
        "icon": "clipboard"
      },
      {
        "text": "Create biomarker compliance dashboard by oncologist",
        "icon": "chart"
      },
      {
        "text": "Establish rapid molecular tumor board review process",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 95,
  "action_steps": [
    {
      "text": "Create reflex testing protocols for CRC and prostate cancer",
      "icon": "document"
    },
    {
      "text": "Implement biomarker tracking system for oncologists",
      "icon": "chart-line"
    },
    {
      "text": "Develop automated biomarker testing reminders",
      "icon": "alert"
    },
    {
      "text": "Establish sample adequacy protocols with pathology",
      "icon": "clipboard"
    }
  ],
  "suggestions": [
    {
      "text": "Consider liquid biopsy program for tissue-limited cases",
      "icon": "document"
    },
    {
      "text": "Analyze turnaround time impact on treatment initiation",
      "icon": "chart-line"
    }
  ],
  "drilldowns": [
    {
      "label": "By Cancer Type",
      "cohort": "Biomarker Testing by Cancer Type",
      "jsonFile": "biomarker-compliance-by-cancer.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Provider",
      "cohort": "Biomarker Testing by Provider",
      "jsonFile": "biomarker-compliance-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Site",
      "cohort": "Biomarker Testing by Site",
      "jsonFile": "biomarker-compliance-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Testing Method",
      "cohort": "Biomarker Testing by Method",
      "jsonFile": "biomarker-compliance-by-method.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Payer",
      "cohort": "Biomarker Testing by Payer",
      "jsonFile": "biomarker-compliance-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Turnaround Time",
      "cohort": "Biomarker Testing Turnaround Time",
      "jsonFile": "biomarker-compliance-tat.json",
      "drilldownLevel": 1
    },
    {
      "label": "NSCLC Detail",
      "cohort": "NSCLC Biomarker Testing",
      "jsonFile": "nsclc-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "CRC Detail",
      "cohort": "CRC Biomarker Testing",
      "jsonFile": "crc-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "Breast Cancer Detail",
      "cohort": "Breast Cancer Biomarker Testing",
      "jsonFile": "breast-biomarker.json",
      "drilldownLevel": 2
    }
  ]
} 